C-Reactive Protein, Interleukin-6, and Vascular Recurrence After Stroke: An Individual Participant Data Meta-Analysis-Reference-Cited by-同舟云学术

C-Reactive Protein, Interleukin-6, and Vascular Recurrence After Stroke: An Individual Participant Data Meta-Analysis

Published:2023-05 Issue:5 Volume:54 Page:1289-1299
ISSN:0039-2499
Container-title:Stroke
language:en
Short-container-title:Stroke

Author:

McCabe John J.¹²³^ORCID,Walsh Cathal¹⁴^ORCID,Gorey Sarah¹²³^ORCID,Harris Katie⁵^ORCID,Hervella Pablo⁶,Iglesias-Rey Ramon⁶,Jern Christina⁷⁸^ORCID,Li Linxin⁹^ORCID,Miyamoto Nobukazu¹⁰,Montaner Joan¹¹¹²¹³¹⁴^ORCID,Pedersen Annie⁷⁸,Purroy Francisco¹⁵¹⁶^ORCID,Rothwell Peter M.⁹^ORCID,Sudlow Catherine¹⁷¹⁸^ORCID,Ueno Yuji¹⁰^ORCID,Vicente-Pascual Mikel¹⁵¹⁶^ORCID,Whiteley William¹⁹¹⁸^ORCID,Woodward Mark⁵²⁰^ORCID,Kelly Peter J.¹²²¹^ORCID

Affiliation:

1. Health Research Board (HRB) Stroke Clinical Trials Network Ireland (SCTNI), Dublin, Ireland (J.J.M., C.W., S.G., P.J.K.).

2. School of Medicine, University College Dublin (UCD), Ireland (J.J.M., S.G., P.J.K.).

3. Department of Geriatric Medicine (J.J.M., S.G.), Mater Misericordiae University Hospital, Dublin, Ireland.

4. Health Research Institute and Mathematics Applications Consortium for Science and Industry (MACSI), Department of Mathematics and Statistics, University of Limerick, Ireland (C.W.).

5. George Institute for Global Health, University of New South Wales, Sydney, Australia (K.H., M.W.).

6. Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neuroscience Research Laboratory, Health Research Institute of Santiago de Compostela, Spain (P.H., R.I.-R.).

7. Department of Laboratory Medicine, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Sweden (C.J., A.P.).

8. Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden (C.J., A.P.).

9. Wolfson Centre for the Prevention of Stroke and Dementia (L.L., P.M.R.), University of Oxford, United Kingdom.

10. Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan (N.M., Y.U.).

11. Department of Neurology, Hospital Universitari Vall d’Hebron, Barcelona, Spain (J.M.).

12. Institute de Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville, Neurology, Spain (J.M.).

13. Virgen Macarena Hospital, Neurology, Sevilla, Spain (J.M.).

14. Neurovascular Research Laboratory, Vall d’Hebron Institute of Research, Universitat Autònoma de Barcelona, Spain (J.M.).

15. Department of Neurology, Hospital Universitari Arnau de Vilanova, Lleida, Spain (F.P., M.V.-P.).

16. Department of Clinical Neurosciences, Institut Reserca Biomèdica Lleida, University of Lleida, Spain (F.P., M.V.-P.).

17. Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics (C.S.), University of Edinburgh, United Kingdom.

18. Centre for Clinical Brain Sciences (C.S., W.W.), University of Edinburgh, United Kingdom.

19. Nuffield Department of Population Health (W.W.), University of Oxford, United Kingdom.

20. George Institute for Global Health, Imperial College London, United Kingdom (M.W.).

21. Department of Neurology (P.J.K.), Mater Misericordiae University Hospital, Dublin, Ireland.

Abstract

Background: Anti-inflammatory therapies reduce recurrent vascular events in coronary disease. Existing studies have reported highly conflicting findings for the association of blood inflammatory markers with vascular recurrence after stroke leading to uncertainty about the potential of anti-inflammatory therapies after stroke and no consensus about the utility of measurement of inflammatory markers in current guidelines. Methods: We investigated the association between hsCRP (high-sensitivity C-reactive protein), IL-6 (interluekin-6), and recurrent major adverse cardiovascular events (MACE), and stroke from individual participant data from 8420 patients with ischemic stroke/transient ischemic attack from 10 prospective studies. We did within-study multivariable regression analyses and then combined adjusted risk ratio (RR) by random-effects meta-analysis. Results: During 18 920 person-years of follow-up, 1407 (16.7% [95% CI, 15.9–17.5]) patients had MACE and 1191 (14.1% [95% CI, 13.4–14.9]) patients had recurrent stroke. On bivariate analysis, baseline IL-6 was associated with MACE (RR, 1.26 [95% CI, 1.10–1.43]) and recurrent stroke (RR, 1.18 [95% CI, 1.05–1.32]), per unit increase log e IL-6. Similar associations were observed for hsCRP (MACE RR, 1.19 [95% CI, 1.09–1.29]; recurrent stroke RR, 1.12 [95% CI, 1.04–1.21], per unit increase log e hsCRP). After adjustment for vascular risk factors and treatment, independent associations remained with MACE (IL-6, RR, 1.12 [95% CI, 1.04–1.21]; hsCRP, RR, 1.09 [95% CI, 1.04–1.15]) and recurrent stroke (IL-6, RR, 1.09 [95% CI, 1.00–1.19]; hsCRP, RR, 1.05 [95% CI, 1.00–1.11]). Comparing the top with the bottom quarters (Q4 versus Q1), IL-6 (RR, 1.35 [95% CI, 1.09–1.67]) and hsCRP (RR, 1.31 [95% CI, 1.07–1.61]) were associated with MACE after adjustment. Similar results were observed for recurrent stroke for IL-6 (RR, 1.33 [95% CI, 1.08–1.65]) but not hsCRP (RR, 1.16 [95% CI, 0.93–1.43]). Conclusions: Blood markers of inflammation were independently associated with vascular recurrence after stroke, strengthening the rationale for randomized trials of anti-inflammatory therapies for secondary prevention after ischemic stroke/TIA.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)

Reference42 articles.

1. Long‐Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta‐Analysis

2. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies

3. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0·5 million Chinese adults

4. Inflammation and Atherosclerosis

5. Inflammation and Stroke Risk: A New Target for Prevention

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-6 and stroke recurrence in ischemic stroke;Biomarkers in Medicine;2024-09-04

2. Monocyte Chemoattractant Protein‐1, Inflammatory Biomarkers, and Prognosis of Patients With Ischemic Stroke or Transient Ischemic Attack: Fndings From a Nationwide Registry Study;Journal of the American Heart Association;2024-08-20

3. C-Reactive Protein: An Important Inflammatory Marker of Coronary Atherosclerotic Disease;Angiology;2024-08-10

4. Weekly Journal Scan: colchicine after an acute ischaemic stroke shows no CHANCE of preventing recurrent events;European Heart Journal;2024-08-05

5. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial;BMJ;2024-06-26